A detailed history of Verition Fund Management LLC transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 22,601 shares of DNLI stock, worth $468,518. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,601
Holding current value
$468,518
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$20.24 - $31.58 $457,444 - $713,739
22,601 New
22,601 $460,000
Q2 2023

Aug 14, 2023

SELL
$23.37 - $32.96 $67,399 - $95,056
-2,884 Reduced 24.48%
8,898 $262,000
Q1 2023

May 15, 2023

BUY
$21.91 - $32.67 $258,143 - $384,917
11,782 New
11,782 $271,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.78B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.